• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Sorafenib Teva
    / Teva


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    30 x 200 mg

    partial basket chart

    Film Coated Tablets

    120 x 200 mg

    partial basket chart

    Film Coated Tablets

    360 x 200 mg

    partial basket chart

    Related information


    Dosage

    The accepted dosage for adults is generally two 200 mg tablets twice a day, which is equivalent to a daily dosage of 800 mg or 4 tablets per day.
    Please refer to the patient leaflet for the complete information.


    Indications

    Treatment of:
    • Patients with advanced renal cell carcinoma.
    • Patients with hepatocellular carcinoma
    • Patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.


    Contra-Indications

    Please refer to the patient leaflet for the complete information.


    Special Precautions

    Please refer to the patient leaflet for the complete information.


    Side Effects

    Please refer to the patient leaflet for the complete information.


    Drug interactions

    Please refer to the patient leaflet for the complete information.


    Pregnancy and Lactation

    Please refer to the patient leaflet for the complete information.


    Overdose

    Please refer to the patient leaflet for the complete information.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel

    סרגל נגישות

    CLOSE